Adagio Medical Announces Positive Pivotal Results for vCLAS^® Ventricular Ablation System

Key Highlights of the Report

• Strong Clinical Outcomes: Adagio Medical Holdings, Inc. (Nasdaq: ADGM) has announced robust six-month results from its FULCRUM-VT Investigational Device Exemption (IDE) clinical trial for the vCLAS^® Ventricular Ablation System. The findings were revealed at the Heart Rhythm Society 2026 conference.
• Primary Effectiveness Endpoints Met:
  • 98% non-inducibility of targeted ventricular tachycardias (VT) at end of procedure
  • 84% freedom from implantable cardioverter defibrillator (ICD) shock at 6 months
  • 59% freedom from any VT recurrence at 6 months
  • Low 2.4% protocol-defined Major Adverse Events rate
• Breakthrough for Both Ischemic and Non-Ischemic Cardiomyopathy: The vCLAS system is the first and only ablation technology to demonstrate equivalent effectiveness in both ischemic (ICM) and non-ischemic cardiomyopathy (NICM) patients, all through an endocardial (internal heart) approach.
• Significant Reduction in ICD Shocks: There was an over 80% reduction in patients experiencing ICD shocks in the six months post-ablation compared to the pre-ablation period.
• Reduction in Medication and Hospital Readmissions: 72% of patients were able to discontinue or reduce their amiodarone dose at six months, and there was a low 1.9% 30-day VT-related hospital readmission rate.

Detailed Trial Results and Clinical Significance

The FULCRUM-VT trial enrolled 209 patients with structural heart disease (including both ICM and NICM) who were indicated for catheter ablation of drug-refractory VT. The study is notable for including one of the most challenging patient cohorts ever treated in a VT ablation trial, with freedom from device intervention (anti-tachycardia pacing or shock) at 6 months being 61% for ICM and 63% for NICM. Freedom from ICD shock at 6 months was 84% for ICM and 85% for NICM, demonstrating consistent outcomes across both patient types.

Mean ablation time per patient was 54 minutes, with an average of 11.5 lesions per patient. The safety profile was strong, with a 2.4% rate of major adverse events, including four (1.9%) peri-procedural deaths, of which only two (1%) were adjudicated as possibly related to the investigational device. All data were adjudicated by independent clinical event committees.

The results also show a significant reduction in the use of toxic antiarrhythmic medication (amiodarone) and hospital readmission rates, underscoring the clinical and potential economic impact of the technology.

Potential Price-Sensitive Information for Shareholders

• FDA Approval Pathway: The strong pivotal results from FULCRUM-VT will be used to support the company’s application for U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) of the vCLAS system. If approved, this could lead to the broadest industry indication for purely endocardial ablation of scar-mediated VT in the United States—a significant commercial opportunity.
• Commercial Availability: The vCLAS^™ Cryoablation System is already commercially available for monomorphic VT in Europe and certain other regions, but is currently investigational in the U.S.
• Market Impact: Ventricular arrhythmias account for approximately 300,000 sudden cardiac deaths annually in the U.S. alone. The FULCRUM-VT study’s promising safety and effectiveness profile—especially in a complex and underserved patient population—positions Adagio Medical for a potentially significant market expansion and revenue growth, contingent on FDA approval.
• Competitive Benchmarking: The FULCRUM-VT results compare favorably to published data on radiofrequency (RF) ablation and emerging pulsed field ablation (PFA) technologies, suggesting the vCLAS system could set a new standard in the field.
• Forward-Looking Statements: Management has highlighted the potential for ULTA technology (Ultra-Low Temperature Ablation) to become foundational for VT treatment and underscored intentions to pursue further research, regulatory approvals, and commercialization. However, all forward-looking statements are subject to risks and uncertainties.

Company Overview

Adagio Medical Holdings, Inc. is focused on developing catheter-based solutions for cardiac arrhythmias. Its proprietary Ultra-Low Temperature Ablation (ULTA) technology is designed to create large, durable lesions in both diseased and healthy cardiac tissue through an endocardial approach. The company’s current focus is on the vCLAS^™ Cryoablation System for ventricular arrhythmias, which is under evaluation in the pivotal FULCRUM-VT U.S. IDE Trial.

Investor Outlook

The announcement of positive pivotal results from the FULCRUM-VT trial represents a major milestone for Adagio Medical. The data not only supports the efficacy and safety of the vCLAS system but also signals a potential paradigm shift in VT ablation treatment, particularly for patients with challenging forms of cardiomyopathy. The forthcoming FDA PMA submission and any subsequent approval could have a material and positive impact on Adagio’s share value and market positioning.

Contact Information

Debbie Kaster
Chief Financial Officer and Chief Business Officer
[email protected]

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors should refer to Adagio Medical Holdings, Inc.’s official filings with the U.S. Securities and Exchange Commission (SEC) for further information on the company’s business, risks, and financial condition. The information provided herein does not constitute a recommendation to buy or sell securities.

View Adagio Medical Holdings, Inc. Historical chart here